Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models

syn74288412

Created By NADIA Bot nadia-bot

doi: 10.1158/1078-0432.CCR-24-2807
pmid: 39786423
dataType: geneExpression drugScreen
studyName: Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models
dataStatus: Available
studyLeads: Sara Ortega-Bertran Eduard Serra
studyStatus: Completed
diseaseFocus: Neurofibromatosis type 1 MPNST
institutions: Germans Trias i Pujol Research Institute (IGTP) Catalan Institute of Oncology (ICO) Bellvitge Biomedical Research Institute (IDIBELL)
fundingAgency: Not Applicable (External Study)
manifestation: MPNST
resourceStatus: approved
alternateDataRepository: insdc.sra:PRJEB83680 insdc.sra:ERP167272
syn74288449
syn74288413
syn74288415

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models page is loading…

Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models

syn74288412

Drop files to upload

Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models page is loading…